Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Cash Adds To Cardiome’s Bargaining Chips

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition-hungry big pharma eyes the firm's oral vernakalant, ready for Phase III.

You may also be interested in...

For Amgen’s Nplate, No News Is Good News

FDA tells biotech the agency will miss once-postponed July 23 user fee date.

Sanofi-Aventis Heart Drug Multaq Back To FDA In Third Quarter

Follow-up ATHENA data bolsters NDA called “not approvable” in 2006.

Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible

Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts